Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
EDITORIAL
(no author information available yet)
No abstract text is available yet for this article.
April 17, 2024: British Journal of Dermatology
#22
EDITORIAL
(no author information available yet)
No abstract text is available yet for this article.
April 17, 2024: British Journal of Dermatology
#23
JOURNAL ARTICLE
Vaishnavee Thote, Susha Dinesh, Sameer Sharma
MDC1 (Mediator of DNA damage Checkpoint protein 1) functions to facilitate the localization of numerous DNA damage response (DDR) components to DNA double-strand break sites. MDC1 is an integral component in preserving genomic stability and appropriate DDR regulation. There haven't been systematic investigations of MDC1 mutations that induce cancer and genomic instability. Variations in nsSNPs have the potential to modify the protein chemistry and their function. Describing functional SNPs in disease-associated genes presents a significant conundrum for investigators, it is possible to assess potential functional SNPs before conducting larger population examinations...
December 2024: Systems Biology in Reproductive Medicine
#24
JOURNAL ARTICLE
Erika Koh, Brett C Neill, John D Ng, Justin J Leitenberger
No abstract text is available yet for this article.
April 16, 2024: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
#25
JOURNAL ARTICLE
Paul Gougis, Anne-Sophie Hamy, Floriane Jochum, Kevin Bihan, Marie Carbonnel, Joe-Elie Salem, Elise Dumas, Rayan Kabirian, Beatriz Grandal, Solenn Barraud, Florence Coussy, Judicael Hotton, Raphaelle Savarino, Aurélien Marabelle, Jacques Cadranel, Jean-Philippe Spano, Enora Laas, Fabien Reyal, Baptiste Abbar
IMPORTANCE: With the widespread use of immune checkpoint inhibitors (ICIs), concerns about their pregnancy outcomes through maternal exposure have emerged, and clinical comparative data are lacking. OBJECTIVE: To assess the risk of pregnancy-, fetal-, and/or newborn-related adverse outcomes associated with exposure to ICIs compared with exposure to other anticancer agents. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, all reports mentioning a pregnancy-related condition and an antineoplastic agent (Anatomical Therapeutic Chemical classification group L01) used for a cancer indication registered in the World Health Organization international pharmacovigilance database VigiBase up to June 26, 2022, were extracted...
April 1, 2024: JAMA Network Open
#26
JOURNAL ARTICLE
Chao Xue, Zhuo Wei, Ye Zhang, Ying Liu, Shuang Zhang, Qi Li, Ke Feng, Xiaoxiao Yang, Guangqing Liu, Yuanli Chen, Xiaoju Li, Zhi Yao, Jihong Han, Yajun Duan
Cytosolic thiouridylase 2 (CTU2) is an enzyme modifying transfer RNAs post-transcriptionally, which has been implicated in breast cancer and melanoma development. And we found CTU2 participated in hepatocellular carcinoma (HCC) progression here. HepG2 cells as well as xenograft nude mice model were employed to investigate the role of CTU2 in HCC development in vitro and in vivo respectively. Further, we defined CTU2 as a Liver X receptor (LXR) targeted gene, with a typical LXR element in the CTU2 promoter. CTU2 expression was activated by LXR agonist and depressed by LXR knockout...
April 17, 2024: Cell Biology and Toxicology
#27
JOURNAL ARTICLE
Ningning Yao, Qingyue Ma, Wendan Yi, Yuanzhang Zhu, Yichong Liu, Xiaodi Gao, Qian Zhang, Wenjuan Luo
PURPOSE: Choroidal melanoma (CM), a kind of malignant tumor, is the main type of Uveal melanoma and one half of CM patients develop metastases. As a member of Eph/ephrin pathway that plays vital role in tumors, EphrinA3 (EFNA3) has been proved to promote tumorigenesis in many tumors. But the effect of EFNA3 in CM has not been studied yet. Through inhibiting angiogenesis, inducing apoptosis and autophagy and so on, Artesunate (ART) plays a key anti-tumor role in many tumors, including CM...
April 17, 2024: Journal of Cancer Research and Clinical Oncology
#28
JOURNAL ARTICLE
Lanqun Qin, Guiying Zhang, Yirong Wu, Yueling Yang, Zhengyun Zou
As one of the scheduled immunization vaccines worldwide, virtually all individuals have been vaccinated with BCG vaccine. In order to verify the hypothesis that delivering BCG high-affinity peptides to tumor areas could activate the existing BCG memory T cells to attack tumor, we firstly predicted the HLA-A*0201 high-affinity peptides of BCG Ag85A protein (KLIANNTRV, GLPVEYLQV), and then, A375 melanoma cells and HLA-A*0201 PBMCs (from PPD-positive adults) were added to co-incubated with the predicted peptides in vitro...
April 17, 2024: Cancer Immunology, Immunotherapy: CII
#29
JOURNAL ARTICLE
Michael Z Zhang, Alexander S Hines, Addison M Demer, Jerry D Brewer
BACKGROUND AND OBJECTIVES: The prognosis of patients diagnosed with melanoma is highly dependent on staging, early detection, and early intervention. In this systematic review, the authors aimed to investigate the impact of surgical delay (time between diagnostic biopsy and definitive surgical excision) on melanoma-specific outcomes. MATERIAL AND METHODS: A systematic review was conducted from Embase (1974-present), MEDLINE (1946-present), Cochrane Central Register of Controlled Trials (2005-present), Scopus, and Web of Science...
April 17, 2024: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
#30
JOURNAL ARTICLE
Iara R T Drakensjö, Mari-Anne Hedblad, Eugenia Colón Cervantes, Ada Girnita
Nevus-associated lentigo maligna and lentigo maligna melanoma (NALMM) are rarely described in the literature and are considered an incidental finding. This study aimed to evaluate the frequency of NALMM and its clinicopathological features. A total of 201 histopathology reports were reviewed and among them 20% of the samples corresponded to NALMM, with females overrepresented in this group (p = 0.02). A significant association was also observed between NALMM with the presence of multiple nevi (p = 0...
April 17, 2024: Acta Dermato-venereologica
#31
JOURNAL ARTICLE
Petra Åkerla, Eero Pukkala, Mika Helminen, Niina Korhonen, Toni Karppinen
Narrow-band TL-01 ultraviolet B phototherapy (TL-01) is an effective and widely used treatment for many skin diseases. The purpose of the investigation was to assess the risk of skin cancers in patients treated with TL-01 phototherapy who have not received any other phototherapy modalities. This cohort study included 4,815 TL-01 treated patients in Finland with psoriasis or atopic dermatitis. Clinical information was collected from the hospital records and linked with Finnish Cancer Registry data. The follow-up started from the first TL-01 treatment and the mean follow-up time was 8...
April 17, 2024: Acta Dermato-venereologica
#32
JOURNAL ARTICLE
Łukasz Łaziński, Mateusz Koziej, Bogusław Antoszewski, Marta Fijałkowska
<b><br>Introduction:</b> Skin cancers constitute a group of medical disorders remaining a field of interest for surgeons and dermatologists. Currently, this group is typically divided into malignant melanoma (MM) and keratinocyte cancers (KC).</br> <b><br>Aim:</b> The aim of this study is to analyze the cases of skin cancers treated in the Department of Plastic, Reconstructive, and Aesthetic Surgery in Lodz (Poland) during the COVID-19 pandemic (from 2020 to 2022) and then compare the results with the ones from the pre-pandemic period (from 2017 to 2019)...
October 12, 2023: Polski Przeglad Chirurgiczny
#33
JOURNAL ARTICLE
Ajami Gikandi, Susan N Chi, Kee Kiat Yeo, Allison F O'Neill, David S Shulman, Steven G DuBois, Natalie B Collins
BACKGROUND: Immune checkpoint inhibitors (ICI) have improved outcomes in a variety of adult cancers and are prescribed with increasing frequency across oncology. However, patterns of off-label use of ICI in pediatrics remain unclear. METHODS: This is a single-institution, retrospective cohort study evaluating off-label ICI use in pediatric and young adult patients with cancer treated at our institution from 2014 to 2022. Response was based on clinician assessment derived from clinical records...
April 2024: Cancer Medicine
#34
JOURNAL ARTICLE
Shravan Leonard-Murali, Chetana Bhaskarla, Ghanshyam S Yadav, Sudeep K Maurya, Chenna R Galiveti, Joshua A Tobin, Rachel J Kann, Eishan Ashwat, Patrick S Murphy, Anish B Chakka, Vishal Soman, Paul G Cantalupo, Xinming Zhuo, Gopi Vyas, Dara L Kozak, Lindsey M Kelly, Ed Smith, Uma R Chandran, Yen-Michael S Hsu, Udai S Kammula
Immune checkpoint inhibition has shown success in treating metastatic cutaneous melanoma but has limited efficacy against metastatic uveal melanoma, a rare variant arising from the immune privileged eye. To better understand this resistance, we comprehensively profile 100 human uveal melanoma metastases using clinicogenomics, transcriptomics, and tumor infiltrating lymphocyte potency assessment. We find that over half of these metastases harbor tumor infiltrating lymphocytes with potent autologous tumor specificity, despite low mutational burden and resistance to prior immunotherapies...
April 16, 2024: Nature Communications
#35
JOURNAL ARTICLE
Rosalind Ashton, Anna N Wilkinson
No abstract text is available yet for this article.
April 2024: Canadian Family Physician Médecin de Famille Canadien
#36
JOURNAL ARTICLE
Sergii Domanskyi, Anuj Srivastava, Jessica Kaster, Haiyin Li, Meenhard Herlyn, Jill C Rubinstein, Jeffrey H Chuang
We designed a Nextflow DSL2-based pipeline, Spatial Transcriptomics Quantification (STQ), for simultaneous processing of 10x Genomics Visium spatial transcriptomics data and a matched hematoxylin and eosin (H&E)-stained whole-slide image (WSI), optimized for patient-derived xenograft (PDX) cancer specimens. Our pipeline enables the classification of sequenced transcripts for deconvolving the mouse and human species and mapping the transcripts to reference transcriptomes. We align the H&E WSI with the spatial layout of the Visium slide and generate imaging and quantitative morphology features for each Visium spot...
April 10, 2024: Cell Rep Methods
#37
REVIEW
T A Sussman, P A Ott
The majority of patients who are diagnosed with cutaneous melanoma are candidates for surgical resection and thus curable from their disease. However, the risk for a recurrence is high for many patients, including those with lymph node-negative melanoma, thus necessitating additional therapies beyond surgery. With the advent of anti-programmed cell death protein 1 (PD-1)-based immunotherapies, which are vastly more effective compared to previous standard-of-care treatments in the advanced setting, the landscape of adjuvant therapy has fundamentally changed in recent years...
April 15, 2024: ESMO Open
#38
JOURNAL ARTICLE
Corrado Mazzaglia, Hafsa Munir, Iek M Le, Magda Gerigk, Yan Yan Shery Huang, Jacqueline D Shields
Lymph nodes (LNs) are organs of the immune system, critical for maintenance of homeostasis and initiation of immune responses, yet there are few models that accurately recapitulate LN functions in vitro. To tackle this issue, an engineered murine LN (eLN) was developed, replicating key cellular components of the mouse LN; incorporating primary murine lymphocytes, fibroblastic reticular cells (FRCs), and lymphatic endothelial cells (LECs). T and B cells compartments are incorporated within the eLN that mimic LN cortex and paracortex architectures...
April 16, 2024: Advanced Healthcare Materials
#39
JOURNAL ARTICLE
Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.
Nina Wyss, Fiamma Berner, Vincent Walter, Ann-Kristin Jochum, Mette T Purde, Marie-Therese Abdou, Tobias Sinnberg, Kathrin Hofmeister, Oltin T Pop, Omar Hasan Ali, Jens Bauer, Hung-Wei Cheng, Mechthild Lütge, Niklas Klümper, Stefan Diem, Zeynep Kosaloglu-Yalcin, Yizheng Zhang, Laura Sellmer, Boris Macek, Julia Karbach, David König, Heinz Läubli, Lars Zender, Britta S Meyer, Christoph Driessen, Christian M Schürch, Wolfram Jochum, Teresa Amaral, Lucie Heinzerling, Antonio Cozzio, Ahmed N Hegazy, Tino Schneider, Martin H Brutsche, Alessandro Sette, Tobias L Lenz, Juliane Walz, Hans-Georg Rammensee, Martin Früh, Elke Jäger, Burkhard Becher, Amanda Tufman, Nicolas Nuñez, Markus Joerger, Lukas Flatz
RATIONALE: Immune checkpoint inhibitor-related pneumonitis is a serious autoimmune event affecting up to 20% of patients with non-small cell lung cancer, yet the factors underpinning its development in some patients and not others are poorly understood. OBJECTIVES: To investigate the role of autoantibodies and autoreactive T cells against surfactant-related proteins in the development of pneumonitis. METHODS: The study cohort consisted of non-small cell lung cancer patients who gave blood samples before and during immune checkpoint inhibitor treatment...
April 16, 2024: American Journal of Respiratory and Critical Care Medicine
#40
JOURNAL ARTICLE
Naveen Kumar Tangudu, Raquel Buj, Hui Wang, Jiefei Wang, Aidan R Cole, Apoorva Uboveja, Richard Fang, Amandine Amalric, Baixue Yang, Adam Chatoff, Claudia V Crispim, Peter Sajjakulnukit, Maureen A Lyons, Kristine Cooper, Nadine Hempel, Costas A Lyssiotis, Uma R Chandran, Nathaniel W Snyder, Katherine M Aird
p16 is a tumor suppressor encoded by the CDKN2A gene whose expression is lost in ~50% of all human cancers. In its canonical role, p16 inhibits the G1-S phase cell cycle progression through suppression of cyclin dependent kinases. Interestingly, p16 also has roles in metabolic reprogramming, and we previously published that loss of p16 promotes nucleotide synthesis via the pentose phosphate pathway. However, the broader impact of p16/CDKN2A loss on other nucleotide metabolic pathways and potential therapeutic targets remains unexplored...
April 16, 2024: Cancer Res Commun
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
